Delineating the ontogeny of an N332-directed anti-HIV-1 broadly neutralising antibody lineage

Simple item page
dc.contributor.authorNaidoo, Thamara
dc.date.accessioned2024-02-22T13:04:40Z
dc.date.available2024-02-22T13:04:40Z
dc.date.issued2024
dc.descriptionA research report submitted in partial fulfilment of the requirement for the degree of Master of Science in Medicine (Vaccinology) to the Faculty of Health Sciences, University of the Witwatersrand, School of Pathology, Johannesburg, 2023
dc.description.abstractBroadly neutralising antibodies (bNAbs) develop in chronically HIV-1 infected individuals and can neutralise a variety of HIV-1 Env strains, making them an important element contributing to the design of HIV-1 vaccines. By understanding and delineating the long affinity maturation pathways that bNAb lineages follow against evolving viruses, it is hoped that this process will be able to be replicated in uninfected people with a series of vaccine immunogens. Investigating the ontogeny of a N332-directed bNAb lineage will provide insights into the key somatic hypermutations necessary for the development of neutralisation breadth. CAP255.G3 is an N332-directed bNAb isolated from CAP255, a participant in the CAPRISA 002 cohort, at 149 weeks post-infection (wpi). Six key antibody intermediates were selected from the CAP255.G3 lineage arm between 17 and 47 wpi, based on their position on a phylogenetic tree and because they contained mutations that were present in broad members of the lineage. We hypothesized that these intermediates would exhibit breadth similar to CAP255.G3. The intermediates were tested against a panel of eight autologous and six heterologous pseudoviruses using a TZM-bl neutralisation assay. The sequence identity of the first heavy chain complementarity-determining region (CDRH1) of CAP255.G3 differed from the closest intermediate and therefore, a CDRH1 chimera was constructed to determine if the CDRH1 from CAP255.G3 affected neutralisation activity. Later intermediates from 39 and 47 wpi, had moderate neutralisation activity against the autologous pseudoviruses, but only theintermediate closest to CAP255.G3 had limited neutralising activity against the heterologous pseudoviruses. Although the CDRH1 chimera had increased neutralisation activity against the heterologous viruses relative to the intermediates, it was less broad and potent than CAP255.G3. This indicates that additional affinity maturation between 47 and 149 wpi, at sites outside of the CDRH1, was required for the development of neutralisation breadth in the CAP255.G3 lineage arm..
dc.description.librarianTL (2024)
dc.facultyFaculty of Health Sciences
dc.identifier.urihttps://hdl.handle.net/10539/37706
dc.language.isoen
dc.schoolSchool of Pathology
dc.subjectAntibodies
dc.subjectOntogeny
dc.subjectHIV-1
dc.subject.otherSDG-3: Good health and well-being
dc.titleDelineating the ontogeny of an N332-directed anti-HIV-1 broadly neutralising antibody lineage
dc.typeDissertation
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
Thamara Naidoo-Abstract_MSc_20230525.pdf
Size:
245.4 KB
Format:
Adobe Portable Document Format
Download
Thumbnail Image
Name:
ThamaraNaidoo_1317469_MScFinal_20230525.pdf
Size:
2.04 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.43 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
*Electronic Theses and Dissertations (Masters)